oseltamivir has been researched along with gefitinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hosseinpour Moghadam, A; Hosseinpour Moghadam, N; Rakhtshah, J; Saidijam, M; Salehzadeh, S; Tanzadehpanah, H | 1 |
1 review(s) available for oseltamivir and gefitinib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for oseltamivir and gefitinib
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Preparation of a highly stable drug carrier by efficient immobilization of human serum albumin (HSA) on drug-loaded magnetic iron oxide nanoparticles.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Cell Proliferation; Chlorocebus aethiops; DNA; Drug Carriers; Drug Compounding; Drug Stability; Ferrosoferric Oxide; Gefitinib; HeLa Cells; Humans; Immobilized Proteins; Inhibitory Concentration 50; Magnetite Nanoparticles; Nevirapine; Organ Specificity; Oseltamivir; Serum Albumin, Human; Silicon Dioxide; Tenofovir; Vero Cells | 2019 |